Thymic Carcinoid Tumor
Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: A primary thymic neuroendocrine tumor, often associated with Cushing syndrome. Two morphologic subtypes are recognized: typical and atypical carcinoid tumors. Atypical carcinoid tumors have a more aggressive clinical course. 
Thymic carcinoid tumors most frequently harbor alterations in MEN1, SMARCA4, PLCG2, HRAS, and ANKRD11 .
SMARCA4 Mutation, MEN1 Mutation, HRAS Mutation, HRAS Missense, and HRAS Codon 61 Missense are the most common alterations in thymic carcinoid tumor .
There are 3 clinical trials for thymic carcinoid tumor, of which 3 are open and 0 are completed or closed. Of the trials that contain thymic carcinoid tumor as an inclusion criterion, 3 are phase 2 (3 open).
SSTR2 is the most frequent gene inclusion criterion for thymic carcinoid tumor clinical trials .
Cabozantinib, atezolizumab, and everolimus are the most common interventions in thymic carcinoid tumor clinical trials.
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.